Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLF – Get Free Report)’s stock price passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $10.49 and traded as high as $10.51. Ono Pharmaceutical shares last traded at $10.51, with a volume of 1,647 shares.
Ono Pharmaceutical Stock Down 4.5 %
The company’s 50-day moving average is $10.49 and its two-hundred day moving average is $12.61. The company has a market cap of $4.94 billion, a P/E ratio of 7.87 and a beta of 0.59.
Ono Pharmaceutical (OTCMKTS:OPHLF – Get Free Report) last released its earnings results on Thursday, October 31st. The company reported $0.24 earnings per share for the quarter. Ono Pharmaceutical had a net margin of 19.64% and a return on equity of 11.80%. The firm had revenue of $824.42 million during the quarter.
Ono Pharmaceutical Company Profile
Ono Pharmaceutical Co, Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia.
Recommended Stories
- Five stocks we like better than Ono Pharmaceutical
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- How to Invest in Blue Chip Stocks
- What Does the Future Hold for Eli Lilly?
- What Are the FAANG Stocks and Are They Good Investments?
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.